---
title: "CAHIC (600195): Won the procurement project of the Jilin Provincial Animal Disease Prevention and Control Center, with a bid amount of 1.936 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288196903.md"
description: "CAHIC announced that it won the bid for the procurement project of the Jilin Provincial Animal Disease Prevention and Control Center, with a bid amount of 1.936 million yuan. The company mainly engages in veterinary drugs, feed, and vaccines, with a revenue of 6.205 billion yuan and a net profit of 171 million yuan in 2025; in the first quarter of 2026, the revenue was 1.509 billion yuan, and the net profit was 24 million yuan"
datetime: "2026-06-01T01:37:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288196903.md)
  - [en](https://longbridge.com/en/news/288196903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288196903.md)
generator: "portal-rs"
---

# CAHIC (600195): Won the procurement project of the Jilin Provincial Animal Disease Prevention and Control Center, with a bid amount of 1.936 million yuan

According to Tongbi Finance, data from Qichacha shows that, based on the "Announcement of the Bidding Results for the Procurement Project of Vaccines for Mandatory Immunization Against Major Animal Epidemic Diseases (Provincial Matching Funds)," China Animal Husbandry Industry Co., Ltd. announced on June 1, 2026, that it won the bid for the procurement project of the Jilin Provincial Animal Epidemic Prevention and Control Center, with a bid amount of 1.936 million yuan.

Related listed company: China Animal Husbandry (600195.SH)

*Tongbi Finance Tip:*

*China Animal Husbandry (600195.SH) had an operating income of 6.205 billion yuan in 2025, with an operating income growth rate of 3.11%. The net profit attributable to the parent company was 171 million yuan, with a net profit growth rate of 141.68%, and a return on net assets of 3.07%.*

*In the first quarter of 2026, the company's operating income was 1.509 billion yuan, with an operating income growth rate of 19.86%. The net profit attributable to the parent company was 24 million yuan, with a net profit growth rate of -62.23%.*

*Currently, the company belongs to the healthcare industry, with main product types including veterinary drugs, feed, and vaccines. The 2025 report shows the main business composition as follows: chemical drugs: 35.81%; trade: 30.96%; feed: 17.74%; biological products: 14.84%; other businesses: 0.64%.*

### Related Stocks

- [600195.CN](https://longbridge.com/en/quote/600195.CN.md)

## Related News & Research

- [Trump signs order to create a U.S. Space Academy](https://longbridge.com/en/news/297356180.md)
- [VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology](https://longbridge.com/en/news/297353256.md)
- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [REG - China Pacific Insur. - Interim DIV. & Adj to the Conversion Price of CB](https://longbridge.com/en/news/297164098.md)
- [Maanshan Iron & Steel reverses RMB 388.43 million inventory write-down provisions in H1 2026](https://longbridge.com/en/news/297338786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**